jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Oesophagectomy Biopsy

Biopsy
image

Report in 240Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histology after esophagus removal.

₹888₹1,269

30% OFF

Oesophagectomy Biopsy - Comprehensive Medical Guide

  • Why is it done?
    • Histopathological examination of esophageal tissue obtained during surgical resection (esophagectomy) to confirm or identify malignancy, particularly esophageal cancer
    • Performed after surgical removal of the esophagus to provide definitive diagnosis and staging of esophageal malignancies, typically adenocarcinoma or squamous cell carcinoma
    • Assesses depth of tumor invasion (TNM staging), presence of dysplasia, and margin involvement to guide post-operative treatment decisions
    • Evaluates for Barrett's esophagus, dysplastic changes, and identifies any residual or concurrent pathological conditions
    • Performed intraoperatively or immediately post-operatively as part of standard surgical pathology processing following esophagectomy
  • Normal Range
    • This is a qualitative histopathological examination without numerical reference ranges
    • NORMAL/NEGATIVE RESULT: Benign esophageal mucosa without dysplasia, malignancy, or Barrett's metaplasia; absence of malignant cells; normal histological architecture maintained
    • ABNORMAL/POSITIVE RESULTS include: presence of malignant cells (adenocarcinoma, squamous cell carcinoma, or other histologic types); high-grade dysplasia; Barrett's esophagus with intestinal metaplasia; lymph node involvement; margin involvement; depth of tumor invasion
    • GRADING: Results reported using TNM staging classification (Tumor size, Nodal involvement, Metastasis) and tumor grade (Well, Moderately, or Poorly differentiated)
    • MARGIN STATUS: Classified as negative (R0), close (<1mm), or positive (R1/R2) based on distance of tumor from resection edges
  • Interpretation
    • MALIGNANCY CONFIRMED: Identifies tumor type (adenocarcinoma most common ~70%, squamous cell ~25%, others ~5%); determines grade of differentiation affecting prognosis
    • DEPTH OF INVASION: Classified as pT1-pT4 (mucosa to adjacent structures); deeper invasion indicates poorer prognosis and may necessitate adjuvant chemotherapy or radiation
    • LYMPH NODE INVOLVEMENT: pN0 (no nodes), pN1-3 (increasing nodal involvement); presence and number of positive nodes significantly impact staging and long-term survival outcomes
    • R0 RESECTION (Negative Margins): Indicates complete tumor removal with adequate normal tissue borders; associated with better long-term prognosis and lower recurrence rates
    • R1/R2 RESECTION (Positive Margins): Indicates incomplete resection with tumor cells at or near surgical margins; strongly indicates need for adjuvant therapy and higher recurrence risk
    • BARRETT'S ESOPHAGUS: Intestinal metaplasia indicates chronic reflux disease; presence increases cancer risk and may require surveillance protocols
    • Factors affecting interpretation: tumor histologic grade, presence of vascular invasion, perineural invasion, inflammatory response, extent of necrosis within tumor
  • Associated Organs
    • PRIMARY ORGAN: Esophagus - the muscular tube connecting pharynx to stomach; site of primary tumor origin in esophageal cancer
    • REGIONAL LYMPH NODES: Mediastinal, gastric, and celiac nodes frequently involved; nodal metastases represent most important prognostic factor beyond primary tumor characteristics
    • ADJACENT ORGANS AT RISK: Stomach (anastomosis site), heart, lungs, aorta; tumor invasion into these structures affects staging and resectability
    • PRIMARY DISEASES DIAGNOSED: Esophageal adenocarcinoma (associated with chronic GERD and Barrett's esophagus); squamous cell carcinoma (associated with smoking and alcohol); esophageal cancer with various risk factors
    • SECONDARY CONDITIONS: Barrett's esophagus (metaplastic change); chronic esophagitis; dysplasia (low-grade or high-grade); complications from tumor including obstruction, hemorrhage, or fistula formation
    • POTENTIAL COMPLICATIONS: Anastomotic leak, stricture formation, vocal cord paralysis (from recurrent laryngeal nerve injury), arrhythmias, pulmonary complications, chylothorax from lymph node dissection
    • METASTATIC SITES: Biologically predicts likelihood of distant metastases to liver, peritoneum, bone, lungs, or distant nodal stations based on tumor characteristics
  • Follow-up Tests
    • TUMOR MARKERS: CEA (Carcinoembryonic antigen) and CA19-9 may be ordered for baseline and surveillance in advanced disease; useful for monitoring response to adjuvant therapy
    • IMAGING STUDIES: CT chest/abdomen/pelvis for staging and surveillance for recurrent disease every 3-6 months during first 2 years; PET-CT if concerned for distant metastases
    • ADJUVANT THERAPY: Oncology consultation recommended for chemotherapy, radiation therapy, or immunotherapy based on TNM stage and margin status
    • IMMUNOHISTOCHEMISTRY: May include HER2 testing, PD-L1 expression, microsatellite instability (MSI) or mismatch repair (MMR) status to guide targeted or immunotherapy options
    • GENOMIC TESTING: Optional molecular profiling to identify specific mutations (TP53, CDKN2A, NOTCH1) that may predict prognosis or response to targeted therapies
    • ENDOSCOPIC SURVEILLANCE: Upper endoscopy may be indicated if positive margins documented to assess remaining esophageal or anastomotic tissue; typically 3-6 months post-operatively
    • PULMONARY FUNCTION TESTS: May be recommended post-operatively if extensive surgical resection performed; useful baseline for detecting post-operative pulmonary complications
    • MONITORING FREQUENCY: 3-6 months during first 2 years, then 6-12 months for years 3-5, then annual; intensity depends on stage and treatment response
  • Fasting Required?
    • NO FASTING REQUIRED - This is an operative/post-operative pathology specimen test, not a blood test
    • PRE-OPERATIVE PREPARATION: Standard NPO (nothing by mouth) status typically 6-8 hours before esophagectomy surgery per anesthesia protocols
    • MEDICATIONS: Continue all essential medications until instructed otherwise; specific cardiac, pulmonary, or anticoagulant medications may require adjustment by surgical team
    • ANTICOAGULANTS: Hold warfarin 5 days pre-operatively and other anticoagulants per surgeon recommendations; bleeding risk assessment critical
    • ASPIRIN: Generally continued perioperatively but specific instructions must come from surgical and anesthesia teams based on individual risk factors
    • SPECIMEN HANDLING: Tissue is typically fixed in formalin immediately in operating room; requires no special patient preparation or fasting
    • POST-OPERATIVE DIET: Resume diet gradually per surgical protocol; typically clear liquids initially, advancing as tolerated; usually 1-2 weeks before normal diet
    • BOWEL PREPARATION: May include preoperative enema or laxative agents per surgeon instructions; typically not required for esophagectomy

How our test process works!

customers
customers